Ombitasvir/Paritaprevir/Ritonavir
- TRADE NAMES: Technivie (AbbVie); Viekira Pak (AbbVie); Viekirax (AbbVie)
- INDICATIONS: Genotype 4 chronic hepatitis C virus infection in patients without cirrhosis (in combination with ribavirin)
- CLASS: CYP3A4 inhibitor (ritonavir), Direct-acting antiviral, Hepatitis C virus NS3/4A protease inhibitor (paritaprevir), Hepatitis C virus NS5A inhibitor (ombitasvir)
- HALF-LIFE: 21–25 hours (ombitasvir); 6 hours (paritaprevir); 4 hours (ritonavir)
FDA APPROVAL DATE: 07/24/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Atazanavir, Carbamazepine, Cisapride, Colchicine, Dihydroergotamine, Dronedarone, Efavirenz, Ergotamine, Ethinyl estradiol-containing medications, Lopinavir, Lovastatin, Lurasidone, Methylergonovine, Midazolam, Midostaurin, Neratinib, Phenobarbital, Phenytoin, Pimozide, Ranolazine, Rifampin, Rilpivirine, Salmeterol, Sildenafil, Simvastatin, St John's Wort, Triazolam, Voriconazole
PREGNANCY CATEGORY: B
pregnancy category will be X when administered with ribavirin
Contra-indicated in patients with moderate or severe hepatic impairment or with known hypersensitivity to ritonavir (see separate entry).
See also separate entry for ribavirin.
Viekira Pak is ombitasvir/paritaprevir/ritonavir co-packaged with dasabuvir.
See also Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir (Viekira XR).
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of this combination in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
